Delving into the Latest Updates on Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology) with Synapse

评价重组三价 HPV 疫苗（16/18/58 型）接种于 18-45 岁中国女性人群的保护效力。在 18-45 岁女性中接种三剂重组三价 HPV 疫苗（16/18/58 型）后可有效预防 HPV16、18 和 58 型别感染相关的高度宫颈异常（CIN 2/3）、原位腺癌（AIS）、浸润性宫颈癌、高级外阴上皮内瘤样病变（VIN 2/3）、高级阴道上皮内瘤样病变（VaIN 2/3）、外阴癌或阴道癌病变的发生。在 18-45 岁女性中接种三剂重组三价 HPV 疫苗（16/18/58 型）后可有效预防 HPV16、18 和 58 型别相关的 12 个月持续感染（PI12）。

[Translation]

To evaluate the protective efficacy of recombinant trivalent HPV vaccine (type 16/18/58) in Chinese females aged 18-45 years. Three doses of recombinant trivalent HPV vaccine (type 16/18/58) in females aged 18-45 years can effectively prevent the occurrence of high-grade cervical abnormalities (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancer, high-grade vulvar intraepithelial neoplasia (VIN 2/3), high-grade vaginal intraepithelial neoplasia (VaIN 2/3), vulvar cancer or vaginal cancer lesions associated with HPV16, 18 and 58 infection. Three doses of recombinant trivalent HPV vaccine (type 16/18/58) in females aged 18-45 years can effectively prevent 12-month persistent infection (PI12) associated with HPV16, 18 and 58.

Start Date17 Oct 2020

Sponsor / Collaborator

Taizhou Tiande Pharmaceutical Co., Ltd.

[+2]

CTR20180525

/ CompletedPhase 2

在18-45岁健康女性受试者中进行的重组三价人乳头瘤病毒（16/18/58型）疫苗（大肠杆菌）单中心I/II期临床试验（第二部分）

[Translation] A single-center phase I/II clinical trial of a recombinant trivalent human papillomavirus (type 16/18/58) vaccine (Escherichia coli) in healthy female subjects aged 18-45 years (Part II)

在中国18-45岁健康女性中，评价不同剂量的重组三价人乳头瘤病毒16/18/58型疫苗（大肠杆菌）的安全性、耐受性和免疫原性

[Translation]

To evaluate the safety, tolerability, and immunogenicity of different doses of a recombinant trivalent human papillomavirus 16/18/58 vaccine (Escherichia coli) in healthy Chinese women aged 18-45 years

Start Date20 Oct 2018

Sponsor / Collaborator

Taizhou Tiande Pharmaceutical Co., Ltd.

[+2]

100 Clinical Results associated with Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology)

Login to view more data

100 Translational Medicine associated with Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology)

Login to view more data

100 Patents (Medical) associated with Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology)

Login to view more data

100 Deals associated with Recombinant HPV-III(16/18/58) Vaccine(Beijing Health Guard Biotechnology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Human Papillomavirus Infection	NDA/BLA	China	Kangle Weishi (Kunming) Biotechnology Co., Ltd.	23 Apr 2025
Human Papillomavirus-Related Cervical Carcinoma	NDA/BLA	China	Kangle Weishi (Kunming) Biotechnology Co., Ltd.	23 Apr 2025
Anal intraepithelial neoplasia	Phase 3	China	Beijing Health Guard Biotechnology, Inc.	30 Jan 2022
Head and Neck Neoplasms	Phase 3	China	Beijing Health Guard Biotechnology, Inc.	30 Jan 2022
Neutropenia	Phase 3	China	Beijing Health Guard Biotechnology, Inc.	30 Jan 2022
Carcinoma in situ of uterine cervix	Phase 3	China	Aihui Import and Export Process For Russia Heihe City Heilongjiang	11 Oct 2021
Carcinoma in situ of uterine cervix	Phase 3	China	Beijing Health Guard Biotechnology, Inc.	11 Oct 2021
Uterine Cervical Dysplasia	Phase 3	China	Beijing Health Guard Biotechnology, Inc.	11 Oct 2021
Uterine Cervical Dysplasia	Phase 3	China	Aihui Import and Export Process For Russia Heihe City Heilongjiang	11 Oct 2021
Hyperplasia of cervix	Phase 3	China	Aihui Import and Export Process For Russia Heihe City Heilongjiang	17 Oct 2020